An observational study in Breast Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Tianjin Medical University Cancer Institute and Hospital · Observational
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital — 34 open to participants now, 34 under way, 1 of them phase 3. Breast Neoplasms · Tianjin Medical University Cancer Institute and Hospital.
Among the 59 studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital, this one is the 9th largest by planned enrollment of the 16 observational ones that give a count, is one of 10 that started in 2025, is one of 16 observational ones, reaches primary completion later than 14 of the 33 other live ones, and was the 50th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →34 of the 59 studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital are open now, in 3 countries. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–70 · Women only
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75 · Women only
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75 · Women only
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 22 · Phase 3 6 · Phase 4 2
First in 2012; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 245 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 100 across the 43 interventional studies, 373 across the 16 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 499 studies on the registry; 298 are open to participants now.
6 of the studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06498154Tianjin Medical University Cancer Institute and HospitalEliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy | 2026-12-30 |
| NCT07254416Tianjin Medical University Cancer Institute and HospitalA Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients | 2026-12-31 |
| NCT07708194Tianjin Medical University Cancer Institute and HospitalEntinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | 2027-02 |
| NCT07831889Tianjin Medical University Cancer Institute and HospitalHypofractionated Radiotherapy After Breast Reconstruction for Breast Cancer | 2027-04-01 |
| NCT07026292Tianjin Medical University Cancer Institute and HospitalSupermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb Lymphedema | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 59 studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.
This study aims to collect clinical data and case information from real-world clinical practice of patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors combined with endocrine therapy.
The main research objectives include: 1. To evaluate the differences in efficacy among different CDK4/6 inhibitors combination regimens in advanced patients; 2. To investigate the subsequent treatment options chosen by patients in the real world after progression on CDK4/6 inhibitors, with the aim of constructing a predictive model for the response to subsequent treatments, thereby providing support for clinical decision-making for both doctors and patients in such situations.
The secondary objectives include: 1. To truly reflect the differences in adverse reactions of different CDK4/6 inhibitors in the Chinese population through the collection of laboratory and imaging results; 2. To collect tumor samples or peripheral blood samples from some patients for genomic and transcriptomic analyses, in preparation for translational research on the mechanism of CDK4/6 inhibitors resistance.
Patients who were diagnosed as HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer between March 2022 to March 2025
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use palbociclib in combination with endocrine therapy as the treatment regimen.
Use abemaciclib in combination with endocrine therapy as the treatment regimen.
Use ribociclib in combination with endocrine therapy as the treatment regimen.
Use dalcetrapib in combination with endocrine therapy as the treatment regimen.
Use other CDK4/6 inhibitors in combination with endocrine therapy (including participation in clinical trials of CDK4/6 inhibitors) as the treatment regimen.
This study also gives PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
rwPFS1 and rwPFS2
Real-world progression-free survival (rwPFS1) during treatment with CDK4/6 inhibitors and real-world progression-free survival (rwPFS2) of subsequent treatment lines selected by clinicians after progression on CDK4/6 inhibitor therapy.
Time frame: 6 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — At the stage of result publication, we will provide the IPD data in accordance with the specific requirements from the ICMJE journal.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tianjin Medical University Cancer Institute and Hospital →